Companies: 10,795·Total market cap: $144.5T
FibroGen, Inc.

FibroGen, Inc.

FGENNASDAQHealthcare
$9.07
$-0.15(-1.63%)
Market Cap$36692186
P/E Ratio
52W High$21.95
52W Low$4.85
Overview

FibroGen, Inc. (FGEN) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

fgen · stock forecast · 14 analysts (3M) · FMP · updated Feb 3, 2026

Analyst Rating & Consensus

Based on 14 Wall Street analysts in the past 3 months

SellBuy

Hold

14 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
7
Sell
2
Strong Sell
0
Total: 14 · Buy rate: 35.7%

12-Month Price Target

High

$28.00

Consensus

$28.00

+254.0% upside

Low

$28.00

Median: $28 · Last Close: $7.91

The FibroGen, Inc. (FGEN) analyst consensus is Hold, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month FGEN price target is $28.00, representing +254.0% upside from the current price of $7.91.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Analyst price target coverage is insufficient to generate a forecast chart for this stock.

Short-Term Price Prediction

Low Activity

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-10$7.623.69%

1-day model range: $7.47–$7.77. Peak: $7.77 (-3.69%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027-50.0%
2028-62.5%
2029-67.2%
2030-69.2%
2031-70.2%
Confidence:Very Low
⚠️ 2027 projections carry Very Low confidence. Treat as directional guidance only.

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)43.4
MACDBEARISH

Moving Averages · FGEN · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$8.00SELL
MA 10$8.12SELL
MA 20$8.53SELL
MA 50$8.68SELL
MA 100$9.71SELL
MA 200$8.95SELL
Current $FGEN · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$7.99SELL
EMA 10$8.14SELL
EMA 20$8.39SELL
EMA 50$8.79SELL
EMA 100$9.12SELL
EMA 200$9.33SELL
Current $FGEN · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2025-09-24
Maintains
BuyBuy
HC Wainwright & Co.2025-08-07
Maintains
BuyBuy
HC Wainwright & Co.2025-05-13
Maintains
BuyBuy
HC Wainwright & Co.2025-03-18
Maintains
BuyBuy
HC Wainwright & Co.2025-02-20
Maintains
BuyBuy
B of A Securities2023-08-08
Downgrade ↓
NeutralUnderperform
Goldman Sachs2023-06-27
Maintains
SellSell
Raymond James2023-06-27
Downgrade ↓
OutperformMarket Perform
B of A Securities2023-06-26
Downgrade ↓
BuyNeutral
Stifel2023-06-26
Downgrade ↓
BuyHold

Wall Street analysts have recently issued updated ratings on FibroGen, Inc. (FGEN) stock. Of the recent 47 rating actions, 11 were upgrades and 15 were downgrades. 14 analysts currently cover FGEN.

Analyst Recommendation Trends

Buy ratings01↑ +1
Hold ratings00
Sell ratings101

FGEN analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$178M

↑ 2807.0% YoY

Revenue Next Year

$7M

↓ 96.3% YoY

EPS This Year

$-20.00

EPS Next Year

$-4.60

↓ 77.0% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast FGEN EPS of $-20.00 for the current fiscal year, based on estimates from 1 analysts. The FGEN revenue forecast is $178M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The FGEN stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus FGEN price target is $28.00 (+254.0% upside), with an analyst consensus of Hold.

The FGEN short-term stock prediction for tomorrow is $7.62 (-3.69%). The FGEN stock prediction for 2030 projects a range of $2–$3.

FibroGen, Inc. trades on NASDAQ under the ticker FGEN. The FGEN stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 36% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

FGEN forecast · 8 questions

According to 14 Wall Street analysts, the average 12-month FGEN price target is $28.00, with a high forecast of $28.00 and a low of $28.00. The median price target is shown in the chart above when available. This implies +254.0% potential upside from the current price of $7.91.

FGEN price targetWhat is FGEN price targetFGEN analyst price targetFGEN 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.